This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT03569007 |
|---|---|
| Status | Terminated |
| Phase | Phase 3 |
| Sponsor | 9 Meters Biopharma, Inc. |
| Enrollment | 307 participants |
| Design | Interventional, Randomized, Parallel, Masking: Triple |
| Conditions | Celiac Disease |
| Interventions | Larazotide; Matching Placebo |
| Start | May 29, 2019 |
| Primary completion | Jul 21, 2022 |
| Study completion | Jul 21, 2022 |
| Results posted | Not yet |
| Registry last updated | Jul 26, 2022 |
Compounds on this site that cite this trial
What the registry says the trial is about
To assess the efficacy and safety of larazotide acetate versus placebo for the relief of persistent symptoms in adult celiac disease patients.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Proportion of subjects who are binary responders | 12 weeks |
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
